New Foundation joins forces to calculate chemistry to develop cancer immunotherapy

HPK1 is a member of the MAP4K family and is an intracellular negative regulatory factor for T-cell proliferation and signaling, which plays an important role in dendritic cell activationHPK1 has been a highly watched target in cancer immunology due to its role in T-cells and dendritic cells, as well as its potential to improve the immune system's cancer surveillanceUntil now, the challenge for HPK1 has been that small molecular inhibitors are often not selective enough to inhibit other T-cell kinases or MAP4K family members while inhibiting HPK1Nimbus Therapeutics has deep computational chemistry expertise and has a long-term partnership with Schr?dinger, a partner of Pharmaceutical Syncantin, to overcome challenges in research and development projects using the company's in silico chemical simulation platformCollaboration allows for rapid design, iteration and optimization of pilot compoundsIn the HPK1 inhibitor project, Nimbus will use its expertise to increase the specificity of HPK1 inhibitors to make them highly selective and powerful in cellular activityHPK1 Structure (Photo: Nimbus's official website)under the terms of the agreement, Nimbus will continue its research and development activities until a specific clinical phase is reachedAt this point, the new base company has the right to exercise its option to acquire the research and development project"We value the innovation soutcomed by the Nimbus team and look forward to bringing new immunotherapies that are powerful to our patients through our joint efforts." DrRobert Hershberg, Executive Vice President of Business Development and Global Alliance, New Base, said"We are pleased to be able to expand our partnership with Celgene and benefit from their capabilities in the development of cancer immunotherapy,"Jeb Keiper, Nimbus's chief executive, addedreference materials:Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy Oncolog inyRetrieved July 9th, 2019, from https://2 s Celgene turns to Nimbus on 'highly lyprized' I/O target - landing right in Bristol-Myers' sweet spot Retrieved July 9, 2019, from https://endpts.com/celgene-turns-to-nimbus-on-highly-prized-i-o-target-landing-right-in-bristol-myers-sweet-spot/